Measles virus turned against breast cancer tumors

NCT ID NCT04521764

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-phase trial is testing a modified measles virus (MV-s-NAP) that is injected directly into tumors in people with metastatic breast cancer. The virus is designed to kill cancer cells and also carry an extra protein to boost the immune response. Researchers are monitoring up to 54 participants to find the safest dose and see if the virus can shrink both injected and non-injected tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
modified measles virus (MV-s-NAP)
What this could lead to
If it works, this could point toward a new way to treat metastatic breast cancer by using a virus to attack tumors and boost the immune system.
What could go wrong
This is a very early phase I trial with only 54 people, so it is not yet known if the virus is safe or effective. The virus may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.